Inquiry Basket
Loading ......
Filter By Product Search for
Norsertraline
Norsertraline Full Name
Norsertraline
Norsertraline Introduction
Norsertraline (N-desmethylsertraline) is the primary circulating metabolite of sertraline and has become increasingly important in pharmacokinetic and pharmacogenomic research rather than as an independent therapeutic agent. Although Norsertraline exhibits substantially weaker serotonin transporter (SERT, encoded by SLC6A4) inhibition than its parent drug, it often reaches higher plasma concentrations during long-term therapy because of its prolonged elimination half-life. For researchers studying antidepressant pharmacology, therapeutic drug monitoring, or individualized medicine, understanding the formation and disposition of Norsertraline is essential. The metabolite is generated predominantly through the activity of CYP2B6 and CYP2C19, while CYP2C9, CYP2D6, and CYP3A4 make smaller contributions. Genetic differences in these metabolic enzymes can significantly influence both sertraline exposure and Norsertraline production, making this metabolite a valuable indicator of drug metabolism and patient-specific pharmacokinetic variability.
Although Norsertraline possesses only modest pharmacological activity compared with sertraline, it remains biologically relevant because it contributes to the overall exposure profile during chronic treatment. Its reduced affinity for SLC6A4 means that it plays a limited direct role in serotonin reuptake inhibition, yet its presence provides important information about metabolic efficiency and enzyme function. Current evidence suggests that CYP2B6 is a major determinant of Norsertraline formation, while CYP2C19 substantially influences overall sertraline metabolism and downstream metabolite production. In addition to inherited genetic variation, factors such as concomitant medications, enzyme inhibition, enzyme induction, age, and hepatic function can alter Norsertraline concentrations. As a result, evaluating metabolite levels together with pharmacogenetic information offers a more comprehensive understanding of antidepressant pharmacokinetics than genotype alone.
Norsertraline is closely associated with diseases commonly treated with sertraline, including major depressive disorder (MDD), generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder (SAD). While the metabolite itself is not considered the primary mediator of therapeutic efficacy, its plasma concentration and metabolite-to-parent drug ratio can provide clinically meaningful insights into drug exposure, treatment adherence, metabolic phenotype, and individualized dose optimization. As precision medicine continues to advance in psychiatry, integrating Norsertraline measurements with CYP2B6 and CYP2C19 genotyping can help explain unexpected treatment responses, identify patients at risk of altered drug metabolism, and support more personalized antidepressant therapy. Consequently, Norsertraline has emerged as an increasingly valuable pharmacokinetic biomarker for both clinical research and therapeutic drug monitoring in modern antidepressant development.
Alternate Names for Norsertraline
Norsertraline
Loading ......
